We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Asthma Medicine Hailed as Effective Treatment for COVID-19

By HospiMedica International staff writers
Posted on 13 Jul 2020
Print article
Image: Asthma Medicine Hailed as Effective Treatment for COVID-19 (Photo courtesy of Queensland University of Technology).
Image: Asthma Medicine Hailed as Effective Treatment for COVID-19 (Photo courtesy of Queensland University of Technology).
Budesonide, a medicine used to help prevent the symptoms of asthma, is being touted as the “silver bullet” for COVID-19.

Budesonide, a corticosteroid or steroid, reduces the severity of asthma attack by preventing inflammation in the lungs and can be inhaled directly to the lungs using a nebulizer. Daily use of inhaled budesonide reduces the number and severity of asthma attacks, although it cannot provide relief from an asthma attack that is already underway. Dr. Richard Bartlett, a US doctor, believes that budesonide, otherwise known as the brand name Pulmicor, can successfully treat the coronavirus. Dr. Bartlett claims to have used inhaled, generic budesonide to cure several COVID-19 patients who have vouched for his treatment.

Now, researchers from the Queensland University of Technology (QUT Brisbane, Australia) and the University of Oxford (Oxford, UK) are collaborating to test common asthma inhalers as a treatment for COVID-19 infection. The STOIC (STerOids In COVID-19) trial will look at whether asthma inhalers given to people with early stage COVID-19 can reduce progression of respiratory illness and cut emergency department presentations and hospital admissions. Some patients will be given budesonide, while others will be given a placebo. Recruitment for the trial has begun and the researchers will be coordinating trial data analysis, modelling of pathological mechanisms and building COVID-19 maths models to explain and use the clinical trial data to optimize patient treatment. Mathematical modelling by the STOIC study team suggests that the earlier the inhaled steroid treatment is applied, the more people can be stopped from becoming sick.

“Ideally it may be that the corticosteroid therapy would be given to anyone with a new, dry cough, and while they are awaiting their COVID test results,” said associate Professor Nicolau, from the QUT Science and Engineering Faculty School of Mathematical Sciences.

Related Links:
Queensland University of Technology
University of Oxford


Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Supplier
12-Channel ECG
CM1200B
New
Uterine Manipulator
GERATI CLERMONT-FERRAND
New
Extracorporeal Shock Wave Therapy Device
Aries 2

Print article
Radcal

Channels

Critical Care

view channel
Image: The new blood test could prevent some of the 350,000 sepsis deaths in the U.S. annually (Photo courtesy of Cytovale)

Sepsis Test Could Save Lives in Emergency Departments, Study Suggests

Sepsis poses a severe, life-endangering illness that arises when an infection triggers a body-wide chain reaction, potentially causing multiple organs to fail quickly. Prompt and accurate diagnosis is... Read more

Surgical Techniques

view channel
Image: Suppressing production of an immune protein could reduce rejection of biomedical implants (Photo courtesy of 123RF)

Protein Identified for Immune Rejection of Biomedical Implants to Pave Way for Bio-Integrative Medical Devices

Biomedical implants like breast implants, pacemakers, and orthopedic devices have revolutionized healthcare, yet a substantial number of these implants face rejection by the body and have to be removed.... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The broad-spectrum POC coagulometer is well-suited for emergency room and emergency vehicle use (Photo courtesy of Perosphere)

Novel POC Coagulometer with Lab-Like Precision to Revolutionize Coagulation Testing

In emergency settings, when patients arrive with a bleed or require urgent surgery, doctors rely solely on clinical judgment to determine if a patient is adequately anticoagulated for reversal treatment.... Read more

Business

view channel
Image: The global surgical lights market is expected to grow by close to USD 0.50 billion from 2022 to 2027 (Photo courtesy of Freepik)

Global Surgical Lights Market Driven by Increasing Number of Procedures

The global surgical lights market is set to witness high growth, largely due to the increasing incidence of chronic illnesses, a surge in demand for cosmetic and plastic surgeries, and untapped opportunities... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.